Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Zytiga
Pharma
ESMO: Novartis' Pluvicto posts mixed prostate cancer data
In stark contrast to an impressive tumor progression showing, Pluvicto was linked to an increased risk of death compared with antiandrogen therapy.
Angus Liu
Oct 23, 2023 10:30am
Roche, Exelixis combo triumphs in prostate cancer trial
Aug 21, 2023 9:57am
FDA signs off on J&J's prostate cancer combo therapy Akeega
Aug 14, 2023 11:52am
FDA panel gives Lynparza narrow backing in prostate cancer
Apr 28, 2023 3:51pm
FDA argues Lynparza only works in prostate cancer subset
Apr 26, 2023 3:06pm
J&J nabs PARP combo's first nod in prostate cancer
Apr 24, 2023 11:20am
